• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3/A filed by Eargo Inc. (Amendment)

    1/5/24 5:09:16 PM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email
    SC 13E3/A 1 ny20014378x8_sc13e3a.htm SC 13E3/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13E-3
    (Amendment No. 2)

    RULE 13E-3 TRANSACTION STATEMENT UNDER
    SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934


    Eargo, Inc.
    (Name of the Issuer)


    Eargo, Inc.
    PSC Echo Parent LLC,
    PSC Echo Merger Sub Inc.,
    PSC Echo, LP,
    PSC Echo GP, LLC
    (Names of Persons Filing Statement)
    Common Stock, Par Value $0.0001 per share
    (Title of Class of Securities)
    Common Stock: 270087109
    (CUSIP Number of Class of Securities)​



    Bill Brownie
    Interim Chief Executive Officer and Chief Operating Officer
    Eargo, Inc.
    2665 North First Street, Suite 300
    San Jose, California 95134
    (650) 351-7700
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Persons Filing Statement)​


      
    With copies to
    Jason Freedman
    Walton Dumas
    Ropes & Gray LLP
    Three Embarcadero Center
    San Francisco, CA 94111
    (415) 315-6300
    Tom Fraser
    Ropes & Gray LLP
    Prudential Tower
    800 Boylston Street
    Boston, MA 02199
    (617) 951-7000
    Oliver Smith
    Michael Gilson
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    (212) 450-4000

    This statement is filed in connection with (check the appropriate box):

    a.
    ☒
    The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
    b.
    ☐
    The filing of a registration statement under the Securities Act of 1933.
    c.
    ☐
    A tender offer.
    d.
    ☐
    None of the above.

    Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

    Check the following box if the filing is a final amendment reporting the results of the transaction: ☐



    ​INTRODUCTION

    This Amendment No. 2 (“Amendment No. 2”) to the Rule 13E-3 Transaction Statement on Schedule 13E-3, together with the exhibits hereto (as amended hereby, this “Schedule 13E-3” or “Transaction Statement”), is being filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), jointly by the following persons (each, a “Filing Person,” and collectively, the “Filing Persons”): (i) Eargo, Inc. (“Eargo” or the “Company”), a Delaware corporation and the issuer of the common stock, par value $0.0001 per share (the “Shares”), that is subject to the Rule 13e-3 transaction, (ii) PSC Echo Parent LLC, a Delaware limited liability company (“Parent”), (iii) PSC Echo Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), (iv) PSC Echo, LP, a Delaware limited partnership and sole member of Parent (“PSC Echo”) and (v) PSC Echo GP, LLC, a Delaware limited liability company and general partner of PSC Echo (“PSC Echo GP”). Parent, Merger Sub, PSC Echo and PSC Echo GP are Filing Persons of this Transaction Statement because they are affiliates of the Company under the SEC rules governing “going-private” transactions.

    On October 29, 2023, the Company, Parent and Merger Sub entered into an Agreement and Plan of Merger (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions and on the terms set forth therein, Merger Sub will merge with and into the Company, with the Company as the surviving corporation (the “Merger”). Concurrently with the filing of this Amendment No. 2, the Company is filing with the SEC Amendment No. 2 to its preliminary Proxy Statement (as amended thereby, the “Proxy Statement”) under Regulation 14A of the Exchange Act, relating to a special meeting of the stockholders of the Company (the “Special Meeting”) at which the stockholders of the Company will consider and vote upon a proposal to (i) approve and adopt the Merger Agreement (ii) approve a non-binding advisory proposal to approve certain compensation arrangements for Eargo’s named executive officers in connection with the Merger and (iii) a proposal to adjourn the Special Meeting, if necessary or appropriate, including adjournments to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to adopt the Merger Agreement. The adoption of the Merger Agreement will require the affirmative vote of the holders of a majority of the voting power of all outstanding Shares entitled to vote, outstanding as of the close of business on the record date for the Special Meeting. A copy of the Proxy Statement is attached hereto as Exhibit (a)(2)(i) and incorporated herein by reference. A copy of the Merger Agreement is attached hereto as Exhibit (d)(i) and is also included as Annex A to the Proxy Statement and incorporated herein by reference.

    Under the terms of the Merger Agreement, if the Merger is completed, each Share outstanding immediately prior to the consummation of the Merger, other than as provided below, will be converted into the right to receive $2.55 in cash (the “Merger Consideration”), without interest and less any applicable withholding taxes. The following Shares will not be converted into the right to receive the Merger Consideration in connection with the Merger: (i) Shares issued and held by the Company and not on behalf of third parties immediately prior to the Merger becoming effective (the “Effective Time”), (ii) Shares owned by PSC Echo or its affiliates, Parent or Merger Sub immediately prior to the Effective Time or Shares held in the treasury of the Company, and (iii) Shares that are issued and outstanding immediately prior to the Effective Time and that have not been voted in favor of the adoption of the Merger Agreement or consented thereto in writing and whose holders have properly exercised and validly perfected appraisal rights with respect to such Shares in accordance with, and who have complied with, Section 262 of the General Corporation Law of the State of Delaware (the “DGCL”), a copy of which is attached hereto as Exhibit (f) and is also included as Annex D to the Proxy Statement and incorporated herein by reference.

    The Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, including the approval and adoption of the Merger Agreement by the Company’s stockholders.

    The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3. Pursuant to General Instruction F to Schedule 13E-3, the information contained in the Proxy Statement, including all appendices thereto, is incorporated in its entirety herein by reference, and the responses to each item in this Schedule 13E-3 are qualified in their entirety by the information contained in the Proxy Statement and the appendices thereto.

    Capitalized terms used but not expressly defined in this Schedule 13E-3 shall have the respective meanings given to them in the Proxy Statement.

    Item 1.   Summary Term Sheet

    The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    Item 2.   Subject Company Information

    (a)   Name and Address.   The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “PARTIES TO THE MERGER”

    (b)   Securities.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “THE SPECIAL MEETING — Voting”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Market Price of Shares of Company Common Stock and Dividends”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Security Ownership of Certain Beneficial Owners and Management”

    (c)   Trading Market and Price.   The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Market Price of Shares of Company Common Stock and Dividends”

    (d)   Dividends.   The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Market Price of Shares of Company Common Stock and Dividends”

    (e)   Prior Public Offerings.   The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Prior Public Offerings”

    (f)   Prior Stock Purchases.   The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Certain Transactions in the Shares of Company Common Stock”

    Item 3.   Identity and Background of Filing Person

    (a)–(c)   Name and Address; Business and Background of Entities; Business and Background of Natural Persons.   Eargo, Inc. is the subject company. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “PARTIES TO THE MERGER”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO”

    “OTHER IMPORTANT INFORMATION REGARDING THE PARENT ENTITIES”

    Item 4.   Terms of the Transaction

    (a)(1)   Tender Offers.   Not Applicable.

    (a)(2)   Merger or Similar Transactions.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Material U.S. Federal Income Tax Consequences of the Merger”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Accounting Treatment”

    “THE SPECIAL MEETING — Vote Required”

    “THE MERGER AGREEMENT”

    Annex A — Agreement and Plan of Merger

    (c)   Different Terms.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE MERGER AGREEMENT — Employee Benefits”

    Annex A — Agreement and Plan of Merger

    Annex B — Voting and Support Agreement

    (d)   Appraisal Rights.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Appraisal Rights”

    “THE MERGER AGREEMENT — Appraisal Shares”

    “THE SPECIAL MEETING — Appraisal Rights”

    “THE MERGER (THE MERGER PROPOSAL — PROPOSAL 1) — Appraisal Rights”

    Annex A — Agreement and Plan of Merger

    Annex D — Section 262 of the DGCL

    (e)   Provisions for Unaffiliated Security Holders.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
     
    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”
     
    “PROVISIONS FOR UNAFFILIATED STOCKHOLDERS”
      
    (f)   Eligibility for Listing or Trading.   Not Applicable.

    Item 5.   Past Contacts, Transactions, Negotiations and Agreements

    (a)   Transactions.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “THE MERGER AGREEMENT”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Certain Transactions in the Shares of Company Common Stock”

    “WHERE YOU CAN FIND MORE INFORMATION”

    Annex A — Agreement and Plan of Merger

    (b)   Significant Corporate Events.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Limited Guarantee”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE MERGER AGREEMENT”

    (c)   Negotiations or Contacts.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “THE MERGER AGREEMENT”

    (e)   Agreements Involving the Subject Company’s Securities.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Intent of the Directors and Executive Officers to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Intent of PSC Echo to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Limited Guarantee”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE MERGER AGREEMENT”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Certain Transactions in the Shares of Company Common Stock”

    “WHERE YOU CAN FIND MORE INFORMATION”

    Annex A — Agreement and Plan of Merger

    Annex B — Voting and Support Agreement

    Item 6.   Purposes of the Transaction and Plans or Proposals

    (b)   Use of Securities Acquired.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Payment of Merger Consideration”

    “THE MERGER AGREEMENT”

    “DELISTING AND DEREGISTRATION OF COMMON STOCK”

    Annex A — Agreement and Plan of Merger

    (c)(1)–(8)   Plans.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Intent of the Directors and Executive Officers to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Intent of PSC Echo to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Limited Guarantee”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE MERGER AGREEMENT”

    “THE SPECIAL MEETING”

    “DELISTING AND DEREGISTRATION OF COMMON STOCK”

    Annex A — Agreement and Plan of Merger

    Annex B — Voting and Support Agreement

    Item 7.   Purposes, Alternatives, Reasons and Effects

    (a)   Purposes.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    (b)   Alternatives.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS—Certain Effects on Eargo if the Merger is not Completed”

    (c)   Reasons.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Opinion of the Special Committee’s Financial Advisor”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    Annex C — Opinion of Perella Weinberg Partners LP

    (d)   Effects.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Plans for the Company After the Merger”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Certain Effects on Eargo if the Merger is not Completed”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Material U.S. Federal Income Tax Consequences of the Merger”

    “SPECIAL FACTORS — Fees and Expenses”

    “SPECIAL FACTORS — Accounting Treatment”

    “SPECIAL FACTORS — Payment of Merger Consideration”

    “THE MERGER AGREEMENT”

    “DELISTING AND DEREGISTRATION OF COMMON STOCK”

    Annex A — Agreement and Plan of Merger

    Item 8.   Fairness of the Transaction

    (a), (b)   Fairness; Factors Considered in Determining Fairness.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Opinion of the Special Committee’s Financial Advisor”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “THE MERGER AGREEMENT”

    Annex C — Opinion of Perella Weinberg Partners LP

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 19, 2023 is attached hereto as Exhibit (c)(ii), and is incorporated by reference herein.

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 28, 2023 is attached hereto as Exhibit (c)(iii), and is incorporated by reference herein.

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 29, 2023, is attached hereto as Exhibit (c)(iv), and is incorporated by reference herein.

    (c)   Approval of Security Holders.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “THE MERGER AGREEMENT — Company Stockholder Approval”

    “THE MERGER AGREEMENT — Conditions to Consummation of the Merger”

    “THE SPECIAL MEETING — Record Date and Quorum”

    “THE SPECIAL MEETING — Vote Required”

    “THE SPECIAL MEETING — Voting”

    “THE SPECIAL MEETING — How to Vote”

    “THE SPECIAL MEETING — Proxies and Revocation”

    Annex A — Agreement and Plan of Merger

    (d)   Unaffiliated Representative.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Opinion of the Special Committee’s Financial Advisor”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    (e)   Approval of Directors.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    (f)   Other Offers.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “THE MERGER AGREEMENT —  No Solicitation; Superior Proposal and Change of Recommendation”

    Annex A — Agreement and Plan of Merger

    Item 9.   Reports, Opinions, Appraisals and Negotiations

    (a)–(c)   Report, Opinion or Appraisal; Preparer and Summary of the Report, Opinion or Appraisal; Availability of Documents.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference.

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Opinion of the Special Committee’s Financial Advisor”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    “WHERE YOU CAN FIND MORE INFORMATION”

    Annex C — Opinion of Perella Weinberg Partners LP

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 19, 2023, is attached hereto as Exhibit (c)(ii), and is incorporated by reference herein.

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 28, 2023, is attached hereto as Exhibit (c)(iii), and is incorporated by reference herein.

    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 29, 2023, is attached hereto as Exhibit (c)(iv), and is incorporated by reference herein.

    Item 10.   Source and Amount of Funds or Other Consideration

    (a), (b)   Source of Funds; Conditions.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Financing of the Merger”

    “SPECIAL FACTORS — Limited Guarantee”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS—Payment of Merger Consideration”

    “THE MERGER AGREEMENT — Consummation and Effectiveness of the Merger”

    “THE MERGER AGREEMENT — Effective Time”

    “THE MERGER AGREEMENT —  Conduct of Business by the Company Prior to Consummation of the Merger”

    “THE MERGER AGREEMENT — Conditions to Consummation of the Merger”

    Annex A — Agreement and Plan of Merger

    (c)   Expenses.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Fees and Expenses”

    “THE MERGER AGREEMENT — Termination of the Merger Agreement”

    “THE MERGER AGREEMENT — Termination Fees and Expenses”

    “THE SPECIAL MEETING — Solicitation of Proxies; Payment of Solicitation Expenses”

    Annex A — Agreement and Plan of Merger

    (d)   Borrowed Funds.

    “SPECIAL FACTORS — Financing of the Merger”

    Item 11.   Interest in Securities of the Subject Company

    (a)   Securities Ownership.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE SPECIAL MEETING — Record Date and Quorum”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Security Ownership of Certain Beneficial Owners and Management”

    Annex B — Voting and Support Agreement

    (b)   Securities Transactions.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE MERGER AGREEMENT”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Certain Transactions in the Shares of Company Common Stock”

    Annex A — Agreement and Plan of Merger

    Annex B — Voting and Support Agreement

    Item 12.   The Solicitation or Recommendation

    (d)   Intent to Tender or Vote in a Going-Private Transaction.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “SPECIAL FACTORS — Intent of the Directors and Executive Officers to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Intent of PSC Echo to Vote in Favor of the Merger”

    “SPECIAL FACTORS — Voting and Support Agreement”

    “THE SPECIAL MEETING — Record Date and Quorum”

    “THE SPECIAL MEETING — Voting Intentions of Eargo’s Directors and Executive Officers”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Directors and Executive Officers of Eargo”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Security Ownership of Certain Beneficial Owners and Management”

    Annex B — Voting and Support Agreement

    (e)   Recommendation of Others.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of the Parent Entities for the Merger”

    “SPECIAL FACTORS — Position of the Parent Entities as to the Fairness of the Merger”

    Item 13.   Financial Statements

    (a)   Financial Information.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “OTHER IMPORTANT INFORMATION REGARDING EARGO — Book Value per Share”

    “WHERE YOU CAN FIND MORE INFORMATION”

    (b)   Pro Forma Information.   Not Applicable.

    Item 14.   Persons/Assets, Retained, Employed, Compensated or Used

    (a)   Solicitations or Recommendations.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Fees and Expenses”

    “THE SPECIAL MEETING — Solicitation of Proxies; Payment of Solicitation Expenses”

    (b)   Employees and Corporate Assets.   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING”

    “SPECIAL FACTORS — Background of the Merger”

    “SPECIAL FACTORS — Purpose and Reasons of Eargo for the Merger; Recommendation of the Eargo Board and the Special Committee; Fairness of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “THE SPECIAL MEETING”

    “THE SPECIAL MEETING — Solicitation of Proxies; Payment of Solicitation Expenses”

    Item 15.   Additional Information

    (b)   The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “SUMMARY TERM SHEET”

    “SPECIAL FACTORS — Certain Effects of the Merger”

    “SPECIAL FACTORS — Interests of Executive Officers and Directors of Eargo in the Merger”

    “THE MERGER AGREEMENT”

    Annex A — Agreement and Plan of Merger

    (c)   Other Material Information.   The entirety of the Proxy Statement, including all appendices thereto, is incorporated herein by reference.

    Item 16.   Exhibits

    The following exhibits are filed herewith:

    Exhibit No.
    ​
    ​
    Description
    (a)(2)(i)
    ​
    ​
    Preliminary Proxy Statement of Eargo, Inc. (included in the Schedule 14A filed on January 5, 2024, and incorporated herein by reference) (the “Preliminary Proxy Statement”).
    (a)(2)(ii)
    ​
    ​
    Form of Proxy Card (included in the Preliminary Proxy Statement and incorporated herein by reference).
    (a)(2)(iii)
    ​
    ​
    Letter to Stockholders (included in the Preliminary Proxy Statement and incorporated herein by reference).
    (a)(2)(iv)
    ​
    ​
    Notice of Special Meeting of Stockholders (included in the Preliminary Proxy Statement and incorporated herein by reference).
    (a)(2)(v)
        E-mail to Employees, dated December 1, 2023 (incorporated by reference to Eargo, Inc.'s Form DEFA14A (filed December 1, 2023) (File No.  001-39616)).
    (a)(5)(i)
    ​
    ​
    Press Release, dated October 30, 2023 (incorporated by reference to Exhibit 99.1 to Eargo, Inc.’s Form 8-K (filed October 30, 2023) (File No. 001-39616)).
    (a)(5)(ii)
    ​
    ​
    August 2023 Presentation (incorporated by reference to Exhibit 99.1 to Eargo, Inc.’s Form 8-K (filed August 10, 2023) (File No. 001-39616)).
    (c)(i)
    ​
    ​
    Opinion of Perella Weinberg Partners LP, dated October 29, 2023 (included as Annex C to the Preliminary Proxy Statement, and incorporated herein by reference).
    (c)(ii)*
    ​
    ​
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 19, 2023.
    (c)(iii)*
    ​
    ​
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 28, 2023.
    (c)(iv)*
       
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 29, 2023.
    (d)(i)
    ​
    ​
    Agreement and Plan of Merger, dated October 29, 2023 by and among Eargo, Inc., PSC Echo Parent LLC and PSC Echo Merger Sub Inc. (included as Annex A to the Preliminary Proxy Statement, and incorporated herein by reference).
    (d)(ii)
    ​
    ​
    Voting and Support Agreement, dated as of October 29, 2023, by and among Eargo, Inc. and PSC Echo, LP (included as Annex B to the Preliminary Proxy Statement, and incorporated herein by reference).
    (f)
    ​
    ​
    Section 262 of the DGCL (included as Annex D to the Preliminary Proxy Statement, and incorporated herein by reference).
    (g)
    ​
    ​
    Not Applicable.
    107*
    ​
    ​
    Filing Fee Table.

    * Previously Filed



    ​SIGNATURES

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


     
    EARGO, INC.
       
     
    By:
    /s/ William Brownie
     
     
    Name:  William Brownie
     
     
    Title:     Interim Chief Executive Officer and Chief Operating Officer

    Date: January 5, 2024


    ​ After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO PARENT LLC
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: January 5, 2024


    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO MERGER SUB INC.
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: January 5, 2024


    ​ After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO, LP
       
     
    By: PSC Echo GP, LLC, its general partner
     
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: January 5, 2024


    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO GP, LLC
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: January 5, 2024


    Get the next $EAR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Eargo, Inc. (0001719395) (Issuer)

    2/20/24 6:03:54 PM ET
    $EAR
    Medical Specialities
    Health Care

    SEC Form 4 filed by Narula Onkarr

    4 - Eargo, Inc. (0001719395) (Issuer)

    2/20/24 6:01:45 PM ET
    $EAR
    Medical Specialities
    Health Care

    Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Eargo, Inc. (0001719395) (Issuer)

    2/20/24 5:59:27 PM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eargo downgraded by William Blair

    William Blair downgraded Eargo from Outperform to Mkt Perform

    9/23/21 7:17:15 AM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo downgraded by JP Morgan with a new price target

    JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

    9/23/21 5:05:21 AM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

    9/23/21 5:03:59 AM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

    SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

    1/31/24 8:00:00 AM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

    SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

    11/1/23 8:00:00 AM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

    SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

    10/26/23 4:01:00 PM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    SEC Filings

    View All

    SEC Form 15-12G filed by Eargo Inc.

    15-12G - Eargo, Inc. (0001719395) (Filer)

    2/26/24 1:39:45 PM ET
    $EAR
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Eargo Inc.

    S-8 POS - Eargo, Inc. (0001719395) (Filer)

    2/21/24 12:44:18 PM ET
    $EAR
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Eargo Inc.

    S-8 POS - Eargo, Inc. (0001719395) (Filer)

    2/21/24 12:44:16 PM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    Leadership Updates

    Live Leadership Updates

    View All

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Eargo Appoints Katie Bayne to Board of Directors

    SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

    6/10/21 4:30:00 PM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

    SC 13D/A - Eargo, Inc. (0001719395) (Subject)

    2/16/24 11:30:56 AM ET
    $EAR
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

    SC 13D/A - Eargo, Inc. (0001719395) (Subject)

    10/30/23 5:21:26 PM ET
    $EAR
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

    SC 13G/A - Eargo, Inc. (0001719395) (Subject)

    1/6/23 11:49:44 AM ET
    $EAR
    Medical Specialities
    Health Care

    $EAR
    Financials

    Live finance-specific insights

    View All

    Eargo Reports Second Quarter 2023 Financial Results

    Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

    8/10/23 4:05:00 PM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo Reports First Quarter 2023 Financial Results

    Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

    5/11/23 4:01:00 PM ET
    $EAR
    Medical Specialities
    Health Care

    Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

    SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

    5/4/23 8:00:00 AM ET
    $EAR
    Medical Specialities
    Health Care